EDAP TMS S.A. develops and manufactures minimally-invasive medical devices for urology applications, leveraging proprietary ultrasound technology. The company's primary products are robotic High Intensity Focused Ultrasound (HIFU) systems for treating prostate cancer and other urological conditions, and Extracorporeal ShockWave Lithotripsy (ESWL) systems for breaking down kidney and urinary tract stones. The company also distributes third-party medical devices including lasers and micro-ultrasound systems.
The business operates through three segments. The HIFU segment manufactures and markets the Focal One robotic system along with related disposables, maintenance services, and treatment leasing arrangements. The ESWL segment produces lithotripters and supplies associated disposables and spare parts. The Distribution segment acts as a reseller and servicer of medical devices from other manufacturers, generating revenue through sales of equipment, consumables, spare parts, and maintenance contracts.
EDAP TMS has a presence across Asia, France, and the United States, serving academic, public, and private hospitals as well as urology clinics through both direct sales channels and third-party distributors. The company employs approximately 310 full-time staff and maintains headquarters in Vaulx-en-Velin, France. It was incorporated in 1979 and is listed on Nasdaq.
No 10-K filings found.